NCT02978482已完成1 期
A Phase 1/2 Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Durvalumab (MEDI4736) in Combination With Tremelimumab in Chinese Patients With Advanced Malignancies
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 26
- 试验地点
- 1
- 主要终点
- Area under the plasma drug concentration-time curve from time zero to Day 28 post-dose (AUC 0-28)
研究概览
简要总结
A Phase 1/2 Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Durvalumab (MEDI4736) in combination with tremelimumab in Chinese Patients with Advanced Malignancies
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 130 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Provision of informed consent prior to any study specific procedures
- •Male or female, aged at least 18 years
- •For Phase 1 PK cohort:
- •Patients with histologically or cytologically confirmed advanced and/or metastatic solid tumors other than HCC refractory or intolerable to existing standard of treatment
- •For Phase 2 cohort:
- •For nasopharyngeal carcinoma:
- •Patients with histologically or cytologically confirmed nasopharyngeal carcinoma must have locally advanced or metastatic disease progressed on or after at least 1 chemotherapy regimen with or without radiotherapy.
- •ONLY FOR PHASE 2 PORTION: mandatory tumor sample
- •No prior exposure to immune-mediated therapy including, but not limited to, other anti CTLA-4, anti-PD-1, anti-PD-L1, and anti-programmed cell death ligand 2 (anti-PD-L2) antibodies, excluding therapeutic anticancer vaccines.
- •Life expectancy ≥12 weeks at Day 1
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- •At least 1 lesion that can be accurately measured at baseline, and that is suitable for repeated measurements as per RECIST 1.1 guidelines.
- •Adequate organ and marrow function
- •Hemoglobin ≥9 g/dL Absolute neutrophil count ≥1.0 × 109 /L Platelet count ≥75 × 109/L Total serum bilirubin ≤1.5×upper limit of normal (ULN) ALT and AST ≤2.5×ULN; for patients with hepatic metastases, ALT and AST ≤5×ULN Calculated creatinine clearance >40 mL/min as determined by Cockcroft-Gault (using actual body weight), or by measured 24-hour urine collection for determination of creatinine clearance.
- •Evidence of post-menopausal status, or negative urinary or serum pregnancy test for female pre-menopausal patients.
排除标准
- •Any concurrent chemotherapy, IP, biologic, or hormonal therapy for cancer treatment. Concurrent use of hormonal therapy for non-cancer-related conditions (eg, hormone replacement therapy) is acceptable. Note: Local treatment of isolated lesions for palliative intent is acceptable (eg, local surgery or radiotherapy).
- •Receipt of last dose of an approved (marketed) anticancer therapy (chemotherapy, targeted therapy, biologic therapy, mAbs, etc) within 21 days prior to the first dose of study treatment. If sufficient washout time has not occurred due to the schedule or PK properties of an agent, a longer washout period will be required, as agreed upon by AstraZeneca and the Investigator.
- •Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks of the first dose of study drug.
- •Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of IP. Note: Local surgery of isolated lesions for palliative intent is acceptable.
- •History of allogenic organ transplantation
- •Any unresolved toxicity National Cancer Institute (NCI) CTCAE Version 4.03 Grade ≥2 from previous anticancer therapy
- •Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [eg, colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], celiac disease, systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis], Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc).
- •Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent
- •History of another primary malignancy
- •History of leptomeningeal carcinomatosis
- •Brain metastases or spinal cord compression unless asymptomatic or treated and stable off steroids and anti-convulsants for at least 14 days prior to study treatment.
- •QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥470 ms calculated.
- •History of active primary immunodeficiency
- •Active infection including tuberculosis, hepatitis B, hepatitis C, or human immunodeficiency virus .
- •Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab (MEDI4736) or tremelimumab.
- •Receipt of live, attenuated vaccine within 30 days prior to the first dose of IP.
- •Female patients who are pregnant or breast-feeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 180 days after the last dose of durvalumab (MEDI4736) plus tremelimumab combination therapy or 90 days after the last dose of durvalumab (MEDI4736) monotherapy.
- •Known allergy or hypersensitivity to IP or any IP excipient, or to other humanized mAbs
- •Prior randomisation or treatment in a previous durvalumab (MEDI4736) and/or tremelimumab clinical study regardless of treatment arm assignment
- •NSCLC patients have history of interstitial lung disease
研究组 & 干预措施
durvalumab
Experimental
durvalumab alone
干预措施: durvalumab (Drug)
durvalumab+tremelimumab
Experimental
durvalumab plus tremelimumab
干预措施: tremelimumab + durvalumab (Drug)
结局指标
主要结局
Area under the plasma drug concentration-time curve from time zero to Day 28 post-dose (AUC 0-28)
时间窗: approximately 6 months after the last evaluable patient is first dosed in phase 1 portion
Only for phase 1 portion of the study
Maximum plasma concentration (Cmax)
时间窗: approximately 6 months after the last evaluable patient in Phase 1 portion is first dosed
Only for phase 1 portion of the study
Trough plasma concentration (Ctrough)
时间窗: approximately 6 months after the last evaluable patient is first dosed in phase 1 portion
Only for phase 1 portion of the study
Adverse event
时间窗: Approximately 12 months after the last evaluable patient from Ph 1 is 1st dosed or the last patient has withdrawn from study or the study discontinued by Sponsor
Objective response rate (ORR)
时间窗: Approximately 12 months after the last evaluable patient is dosed, or the last patient has withdrawn from the study or the study is discontinued by the sponsor.
Only for phase 2 portion of the study (Phase 2 part withdrawn without initiation)
次要结局
- Anti-drug antibody (ADA)(approximately 12 months after the last evaluable patient is first dosed, or the last patient has withdrawn from the study, or the study is discontinued by the Sponsor)
- Complete response/Partial response/Stable disease/Progressive disease(approximately 6 months after the last evaluable patient is first dosed in phase 1 portion)
- Overall survival (OS)(approximately 12 months after the last evaluable patient is first dosed, or the last patient has withdrawn from the study, or the study is discontinued by the Sponsor)
- Anti-drug antibody neutralizing antibodies (ADA nAB)(approximately 12 months after the last evaluable patient is first dosed, or the last patient has withdrawn from the study, or the study is discontinued by the Sponsor)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
1 期
A Study of 3HP-2827 in Treatment of Unresectable or Metastatic Solid Tumors With FGFR2 AlterationsSolid Tumors With FGFR2 Alterations, AdultNCT063785933H (Suzhou) Pharmaceuticals Co., Ltd.130
进行中（未招募）
1 期
Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell MalignanciesPhase I: Relapsed or Refractory B-cell MalignanciesPhase II Cohort A: Relapsed or Refractory Mantle Cell LymphomaPhase II Cohort B: Relapsed or Refractory Chronic Lymphocytic LeukemiaNCT03932331AstraZeneca105
撤回
2 期
A Phase 2, Multicenter, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pefcalcitol Ointment, 0.005%, Applied Topically Twice Daily (BID) for 8 Weeks in Adolescent Subjects 12 to < 17 Years of Age With Plaque PsoriasisPsoriasisNCT02970331Maruho Co., Ltd.
招募中
2 期
A Study of HB0025 Injection in Patients With Advanced Renal CancerRenal CancerNCT06222125Huabo Biopharm Co., Ltd.100
撤回
1 期
NTLA-3001 in Adults with Alpha-1 Antitrypsin Deficiency-Associated Lung DiseaseLung DiseasePulmonary DiseaseAlpha-1 Antitrypsin Deficiency-associated Lung DiseaseAATDAlpha-1 Antitrypsin DeficiencyNCT06622668Intellia Therapeutics30